Co-Authors
This is a "connection" page, showing publications co-authored by JIANJUN GAO and JENNIFER WARGO.
Connection Strength
0.547
-
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
Score: 0.147
-
Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9.
Score: 0.142
-
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 09 23; 12(1):5606.
Score: 0.050
-
B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.
Score: 0.045
-
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A. 2019 10 29; 116(44):22246-22251.
Score: 0.044
-
Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2019 Jan; 25(1):188.
Score: 0.041
-
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018 12; 24(12):1804-1808.
Score: 0.041
-
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097.
Score: 0.037